Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
blosozumab
- Development stage
- Phase 2
- Lead developer
- Transcenta
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous (investigational)
01
Overview
Blosozumab is a humanized IgG4 monoclonal antibody that targets sclerostin (SOST), a glycoprotein that acts as a negative regulator of bone formation. By binding to and inhibiting SOST, blosozumab promotes osteoblast activity and increases bone formation, leading to improved bone mineral density (BMD). It is being developed primarily for the treatment of osteoporosis in postmenopausal women and men with low BMD. Clinical trials have shown dose-dependent increases in lumbar spine, total hip, and femoral neck BMD with good tolerability. Blosozumab was originally developed by Eli Lilly and Company; Transcenta Holding has since licensed rights for development in Greater China[1][2][3][4][5][7][10].
- Other names
- blosozumabanti-SOST(sclerostin) monoclonal antibody
02
Targets
SOST (Sclerostin)
Beyond the preview
Go deeper on blosozumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on blosozumab.